Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 6;20(1):16.
doi: 10.1186/s12936-020-03544-7.

KASP: a genotyping method to rapid identification of resistance in Plasmodium falciparum

Affiliations

KASP: a genotyping method to rapid identification of resistance in Plasmodium falciparum

Ana Alvarez-Fernandez et al. Malar J. .

Abstract

Background: The emergence and spread of anti-malarial resistance continues to hinder malaria control. Plasmodium falciparum, the species that causes most human malaria cases and most deaths, has shown resistance to almost all known anti-malarials. This anti-malarial resistance arises from the development and subsequent expansion of Single Nucleotide Polymorphisms (SNPs) in specific parasite genes. A quick and cheap tool for the detection of drug resistance can be crucial and very useful for use in hospitals and in malaria control programmes. It has been demonstrated in different contexts that genotyping by Kompetitive Allele Specific PCR (KASP), is a simple, fast and economical method that allows a high-precision biallelic characterization of SNPs, hence its possible utility in the study of resistance in P. falciparum.

Methods: Three SNPs involved in most cases of resistance to the most widespread anti-malarial treatments have been analysed by PCR plus sequencing and by KASP (C580Y of the Kelch13 gene, Y86N of the Pfmdr1 gene and M133I of the Pfcytb gene). A total of 113 P. falciparum positive samples and 24 negative samples, previously analysed by PCR and sequencing, were selected for this assay. Likewise, the samples were genotyped for the MSP-1 and MSP-2 genes, and the Multiplicity of Infection (MOI) and parasitaemia were measured to observe their possible influence on the KASP method.

Results: The KASP results showed the same expected mutations and wild type genotypes as the reference method, with few exceptions that correlated with very low parasitaemia samples. In addition, two cases of heterozygotes that had not been detected by sequencing were found. No correlation was found between the MOI or parasitaemia and the KASP values of the sample. The reproducibility of the technique shows no oscillations between repetitions in any of the three SNPs analysed.

Conclusions: The KASP assays developed in this study were efficient and versatile for the determination of the Plasmodium genotypes related to resistance. The method is simple, fast, reproducible with low cost in personnel, material and equipment and scalable, being able to core KASP arrays, including numerous SNPs, to complete the main pattern of mutations associated to P. falciparum resistance.

Keywords: Cytb; K13; KASP; MDR; Plasmodium falciparum; Resistance; SNPs.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
A schematic approach to the KASP mechanism of action
Fig. 2
Fig. 2
Graphics showing genotypes of the Pfmdr1 (a), Pfcytb (b) and Pfk13 (c) genes, as well as a grouping of the data set (D). Red ovals correspond to WT genotype, blue to mutated genotype, yellow to heterozygous genotypes and green negative controls samples and non-template controls (NTC). Red dots correspond to positives samples that were not detected due to their low parasitaemia. WT wild type, HZ heterozygous type, M mutated type

References

    1. WHO. World malaria report 2019. Geneva: World Health Organization; 2019.
    1. Otienoburu S, Suay I, Garcia S, Thomas N, Srisutham S, Björkman A, et al. An online mapping database of molecular markers of drug resistance in Plasmodium falciparum: the ACT Partner Drug Molecular Surveyor. Malar J. 2019;18:12. doi: 10.1186/s12936-019-2645-x. - DOI - PMC - PubMed
    1. Cowell A, Winzeler E. The genomic architecture of antimalarial drug resistance. Brief Funct Genomics. 2019;18:314–328. doi: 10.1093/bfgp/elz008. - DOI - PMC - PubMed
    1. Hartl D. The origin of malaria: mixed messages from genetic diversity. Nat Rev Microbiol. 2004;2:15–22. doi: 10.1038/nrmicro795. - DOI - PubMed
    1. WHO. Artemisinin resistance and artemisinin-based combination therapy efficacy. Geneva: World Health Organization; 2018.

MeSH terms

LinkOut - more resources